---
title: "Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296164347.md"
description: "Australian biotechnology giant CSL saw its shares surge 18%, marking its best intraday session since 2001, after reporting better-than-expected annual underlying earnings. The company forecast growth for 2027 driven by its core plasma division, boosting investor confidence in the world's top flu vaccine maker."
datetime: "2026-08-18T01:48:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296164347.md)
  - [en](https://longbridge.com/en/news/296164347.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296164347.md)
generator: "portal-rs"
---

# Australia's CSL surges 18% on earnings beat, upbeat plasma business forecast

By Sherin Sunny and Nikita Maria Jino Aug 18 (Reuters) - CSL reported better-than-expected annual underlying earnings on Tuesday and forecast growth in 2027 on the back of its core plasma division, sending the Australian biotechnology giant's shares up 18% in their best intraday session since 2001. CSL, among the world's top flu vaccine makers, posted underlying net profit after tax attributable

### Related Stocks

- [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md)
- [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md)

## Related News & Research

- [CSL Director Exercises Rights to Acquire Additional Shares](https://longbridge.com/en/news/297138232.md)
- [CSL: Significant impairments led to a net loss, but cost savings and strong cash flow support future growth](https://longbridge.com/en/news/296150629.md)
- [CEO of Australia’s US$255 billion sovereign wealth fund quits](https://longbridge.com/en/news/297009111.md)
- [Paysign Targets $117M Revenue as Patient-Affordability Business Surges](https://longbridge.com/en/news/297285098.md)
- [CSL Posts Loss In FY26 On Restructuring Costs, Impairments](https://longbridge.com/en/news/296181246.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**